Adult Langerhans cell histiocytosis presenting with multisystem involvement and sarcomatoid features: a case report

Luis E. Aguirre, Ingrid Schwartz, Jennifer Chapman, Marcelo F. Larsen and Alvaro Alencar*

Abstract

Background: Langerhans cell tumors are rare clonal disorders characterized by neoplastic proliferation of dendritic cells that can be further classified into the subtypes Langerhans cell histiocytosis and Langerhans cell sarcoma, which are rare neoplasms exhibiting aggressive features and a poor prognosis. In addition to illustrating the refractoriness and poor outcomes of multisystem Langerhans cell histiocytosis in adults, specific events in this case highlight important characteristics of disease biology that warrant detailed discussion and exposition to a wider audience.

Case presentation: We describe the case of a 42-year-old Caucasian man with Langerhans cell histiocytosis diagnosed from a lesion on the left arm that presented with constitutional symptoms, early satiety, and weight loss. Esophagogastroduodenoscopy showed extensive esophageal and duodenal involvement by Langerhans cell histiocytosis with features of Langerhans cell sarcoma. He was initially treated for Langerhans cell histiocytosis with low doses of cytarabine until he eventually presented clear transformation to acute monoblastic leukemia with complex karyotype that could not be properly controlled, leading eventually to death.

Conclusions: Langerhans cell histiocytosis remains an exceedingly rare entity in adults, frequently presenting as multisystem disease with risk organ involvement. Langerhans cell sarcoma represents an aggressive subtype with extremely poor prognosis for which intensive acute myeloid leukemia induction should be strongly considered.

Keywords: Langerhans cell histiocytosis, Langerhans cell sarcoma, Cytogenetics, Acute myeloid leukemia, Colony-stimulating factor, Leukemic transformation, Chemotherapy, Central nervous system

Background

Langerhans cell tumors are rare clonal disorders characterized by neoplastic proliferation of dendritic cells with distinctive protein expression (CD1a/langerin/S100) and ultrastructural features (Birbeck granules) with Langerhans cell histiocytosis (LCH) and Langerhans cell sarcoma (LCS) subtypes [1–3]. Historically, LCH has been classified as a unifocal disease, multifocal unisystem disease, or multifocal multisystem disease [2]. LCS is a rare neoplasm exhibiting aggressive features that carries a poor prognosis. We report a case of a patient with a presentation with symptomatic multisystem multifocal LCH disease with early suggestion of leukemic transformation with particular sensitivity to growth factors. In addition to illustrating the refractoriness and poor outcomes of multisystem LCH in adults, specific events in this case highlight important characteristics of disease biology that warrant detailed discussion and exposition to a wider audience to raise awareness of this unusual entity and aid in the earlier identification of its potential complications.
Case presentation
A 42-year-old Caucasian man presented to our hospital with acute onset of fatigue, nausea, vomiting, early satiety, diarrhea, and weight loss 3 months after LCH had been diagnosed on the basis of biopsy of an asymptomatic lesion on the left arm. His physical examination was pertinent for tender hepatosplenomegaly and multiple eczematous papular lesions on the trunk and extremities. His complete blood count (CBC) results and lactate dehydrogenase (LDH) level were normal. Esophagogastroduodenoscopy (EGD) demonstrated herpes esophagitis and *Helicobacter pylori* gastritis. Biopsies of the duodenum and esophagus showed involvement by LCH with features suggestive of LCS (Fig. 1). The *BRAF V600E* mutation was not detected. Imaging did not demonstrate any suspicious bone or central nervous system (CNS) involvement. His bone marrow biopsy (BMBx) showed no LCH or acute myeloid leukemia (AML). He was started on intravenous cytarabine 100 mg/m² daily for 5 days every 4 weeks, which led to improvement but no resolution of his skin lesions or gastrointestinal (GI) symptoms. After four cycles, his therapy was adjusted to every 2 weeks in view of kinetic failure. This adjustment led to clinical improvement, but his LDH level continued to rise, leading to repeat BMBx performed after cycle 8, which showed no evidence of AML.

Three weeks later, he presented with acute left hemianopia resulting from an ischemic cerebrovascular accident. Workup demonstrated circulating blasts, spontaneous tumor lysis syndrome, and disseminated intravascular coagulation (DIC). BMBx confirmed acute monoblastic leukemia with a complex karyotype. Next-generation sequencing (NGS) showed no additional mutations. The patient was started on induction 7 + 3 (daunorubicin/cytarabine), which led to transient resolution of skin lesions that quickly worsened by day 15. The lesions appeared as multiple erythematous papules and nodules throughout the back. Histological sections showed heavily epidermotropic and bandlike dermal infiltrates of leukemic cells in the dermis with pseudo-blisters formed by tumor necrosis (Fig. 2a). A subset of tumor cells showed features of Langerhans cells, including reniform nuclei and atypical large and hyperchromic nuclei (Fig. 2b). Immunophenotyping revealed that the...
Fig. 2 Punch biopsy of the skin showing superficial epidermal involvement by a hematopoietic neoplasm. Epidermal erosion and ulceration with underlying hematopoietic infiltrate involving epidermis and upper dermis (A; H&E stain, 100× magnification). The hematopoietic neoplasm is poorly differentiated with blastic nuclear features and round to reniform nuclei. Cellular apoptosis is increased. Numerous small reactive lymphoid cells are also present (B; 500× magnification). The majority of the blastic cells express CD1a by immunohistochemistry (C; 500× magnification) and coexpress langerin (D; 500× magnification). The findings are those of acute monoblastic leukemia with Langerhans cell differentiation involving skin.

Fig. 3 T1-weighted magnetic resonance imaging (MRI) of the brain with contrast enhancement (sagittal view) and cerebrospinal fluid analysis. Leptomeningeal involvement by acute myeloid leukemia demonstrated by brain MRI with contrast (A) with diffuse pachymeningeal thickening and enhancement overlying the bilateral cerebral hemispheres (white arrows) and cerebrospinal fluid showing abnormal hypercellularity due to the presence of monoblasts (B and C; Wright Giemsa stain at 200× and 1000× magnification, respectively).
tumor cells were positive for langerin, S100, and CD1a with intratumoral heterogeneity and a Ki67 showing a nearly 80% cell proliferation rate (Fig. 2c, d). The tumor cells were also positive for CD56, CD117, and CD123 in a subset of cells. The immunophenotype supported both myelomonoblastic and Langerhans cell differentiation. Marrow cytogenetics detected t(13;14) in all tumor cells and additional structural abnormalities involving chromosomes 1, 8, 9, 10, and Y. In this particular context, the chromosome lesions were best classified as cutaneous involvement of LCH. Cytogenetic profiling with NGS showed nonsynonymous mutation p.E69K affecting the PTPN11 gene (SHP2), homozygous loss of CDKN2A at 9p21, and a tumor mutational burden of 26%.

He was started on salvage therapy with CLAG-M (cladribine 5 g/m², cytarabine 2 g/m², granulocyte colony-stimulating factor (G-CSF), mitoxantrone 10 g/m²), and after the first dose of filgrastim (G-CSF), he developed acute diplopia with leptomeningeal involvement by AML as identified by brain magnetic resonance imaging and lumbar puncture (Fig. 3). Intensive intrathecal therapy with methotrexate (MTX) was initiated twice per week for six cycles. The patient's skin lesions and neurologic symptoms resolved with restaging consistent with complete remission. However, 1 week later, his skin lesions recurred, followed by recurrence of neurologic deficits that responded poorly to salvage therapy, including high-dose cytarabine, further intrathecal therapy, and CNS radiation. The patient died 1 year after diagnosis of LCH while undergoing treatment with MTX and cytarabine as a bridge to marrow transplant. Table 1 summarizes the cardinal features associated with this case.

**Discussion and conclusions**

LCH is a rare entity that results from atypical clonal proliferation of a subset of mononuclear dendritic cells closely resembling Langerhans cells that derive from myeloid progenitor cells. Somatic mutations activating the MAPK (mitogen-activated protein kinase) signaling pathway are commonly observed in LCH, with BRAF V600E mutation identified in over half cases [6, 7]. LCH is mostly described and studied in children [1]. Median age at the time of diagnosis is 1–3 years with an annual incidence of 3-5 cases per million persons per year in children and 1-2 cases per million persons per year in adults [2, 3]. LCH is further stratified into single-system disease with unifocal or multifocal involvement or multifocal multisystem disease with or without risk organ (marrow, liver, or spleen) involvement [1–3]. The majority of adults present with multisystem involvement mostly characterized by osteolytic lesions, skin or mucocutaneous involvement, diabetes insipidus, and hepatosplenomegaly. CNS or GI compromise is uncommon [8–10]. Prognosis correlates with extent of disease and degree of organ dysfunction, with more than half presentations with multisystem disease dying of LCH [4, 11].

| Table 1 Oncologic history/summary |
|----------------------------------|
| **January 2017**: Skin biopsy showed LCH |
| **February 2017**: Progressive nausea/diarrhea, weight loss |
| **March 2017**: EGD - herpes esophagitis, Barrett’s esophagus, Helicobacter pylori gastritis, Langerhans cell sarcoma in stomach-duodenum, Acyclovir full dose, triple therapy (could not tolerate) |
| **April 2017**: Persistent nausea/emesis, weight loss |
| **EGD**: Resolved herpes esophagitis, Barrett’s esophagus, persistent gastritis, Langerhans cell sarcoma in stomach-duodenum |
| **PET/CT**: Diffuse uptake in bone marrow, and GI tract |
| **Brain MRI** (-) |
| **Bone MRI**: Diffuse marrow changes, no bone lesions |
| **Normal CBC, LDH** |
| **BMBx** (-) |
| **May 2017**: Cytarabine 100 mg/m²/d x 5 d |
| **July 2017**: EGD/colonoscopy post C3 - still significant erythema, biopsy (+) |
| **August 2017**: Improved but persistent symptoms |
| **Skin biopsy** - LCH |
| **September 2017**: C6 - switch to every 2 weeks |
| **October 2017**: BMBx post C7 - No evidence of disease, dyspoiesis likely from chemo, (-) AML FISH and myeloid NGS |
| **November 2017**: Right posterior cerebral artery [PCA] thrombus s/p TPA |
| **Circulating blasts**: BMBx - acute monoblastic leukemia |
| **Karyotype**: 45,X,Y,der(13;14)(q10;q10) |
| 45,X,del(Y)(t(Y;7)(q11.2;q71)), s1, del(1)(q11),+9(1p10q10), del(8)(t(1;8)(q10p10)), del(10)(p11.2) |
| **AML NGS** (-), **FISH** (-) |
| **November 2017**: 7 + 3 - D15: Recurrent skin lesions |
| **BMBx** - persistent AML |
| **Karyotype**: 45,X,Y,der(13;14)(q10q10) |
| **Skin lesion**: Leukemia cutis with LCH |
| **(+)** AML NGS PTPN11 mutation |
| **FISH** (+) homozygous del 9p21 |
| **December 2017**: CLAG-M - diplopia on D1 |
| **(+)** MRI and LP for CSF involvement |
| **LP** with IT chemo 2x/week × 6 - (-) first LP |
| **Recovery marrow - CR** |
| **January 2018**: HIDAC 3 g/m² × C1 + IT |
| **February 2018**: Cytarabine 2 g/m² + cladribine 5 mg/m² + mitoxantrone 10 mg/m² + IT |
| **March 2018**: MTX 5 g/m² + cytarabine 3 g/m² as a bridge to transplant due to new skin lesions + IT |

AML acute myeloid leukemia, BMBx bone marrow biopsy, CBC complete blood count, CR complete response, CLAG-M cladribine, cytarabine, granulocyte colony-stimulating factor, mitoxantrone, CR complete response, Day day number, EGD esophagogastroduodenoscopy, FISH fluorescent in situ hybridization, GI gastrointestinal, HIDAC high-dose cytarabine, IT intrathecal, LCH Langerhans cell histiocytosis, LDH lactate dehydrogenase, LP lumbar puncture, MRI magnetic resonance imaging, MTX methotrexate, NGS next generation sequencing, PTPN11 Protein tyrosine phosphatase, non-receptor type 11, TPA tissue plasminogen activator

LCS, reported mainly in adults, is extremely rare. Differentiation from LCH is challenging because immunophenotype is identical and diagnosis is based on overtly malignant pleomorphic appearance [11–15].

Therapy is extrapolated from pediatric studies and single-institution experiences because clinical trials in adults are lacking [16]. Although the commonly used pediatric approach with vinblastine and prednisone is
| Study title (ClinicalTrials.gov identifier) | Interventions | Study design | Locations |
|-------------------------------------------|--------------|-------------|-----------|
| AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis (NCT04121819) | Drug: Cytarabine | Intervention model: Single-group assignment<br>Masking: None (open label)<br>Primary purpose: Treatment | Peking Union Medical College Hospital, Beijing, China |
| Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders (NCT02425904) | Drug: Clofarabine | Allocation: Nonrandomized<br>Intervention model: Single-group assignment<br>Masking: None (open label)<br>Primary purpose: Treatment | Phoenix Children’s Hospital, Phoenix, AZ, USA<br>Arkansas Children’s Hospital, Little Rock, AR, USA<br>Children’s Hospital of Los Angeles, Los Angeles, CA, USA (and 12 more) |
| LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis (NCT02205762) | Drug: Prednisone<br>Drug: Mercaptopurine (and 6 more) | Allocation: Randomized<br>intervention model: Parallel assignment<br>Masking: None (open label)<br>Primary purpose: Treatment | Children’s Hospital of Alabama, Birmingham, AL, USA<br>Phoenix Children’s Hospital, Phoenix, AZ, USA<br>Arkansas Children’s Hospital, Little Rock, AR, USA (and 28 more) |
| Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis (NCT04120519) | Drug: Thalidomide combined with dexamethasone and cyclophosphamide | Intervention model: Single-group assignment<br>Masking: None (open label)<br>Primary purpose: Treatment | Peking Union Medical College Hospital, Beijing, China |
| Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) (NCT02670707) | Drug: Cytarabine<br>Drug: Vinblastine/ prednisone | Allocation: Randomized<br>intervention model: Parallel assignment<br>Masking: None (open label)<br>Primary purpose: Treatment | Texas Children’s Hospital, Houston, TX, USA |
| Denosumab for the Treatment of Adult LCH (NCT03270020) | Drug: Denosumab 70 mg/ml (XGEVA; Amgen, Charlotte, NC, USA) | Intervention model: Single-group assignment<br>Masking: None (open label)<br>Primary purpose: Treatment | 251 Hellenic Air Force and VA Athens General Hospital, Department of Endocrinology, Attiki, Greece |
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders (NCT04079179) | Drug: Cobimetinib | Allocation: Nonrandomized<br>intervention model: Parallel assignment<br>Masking: None (open label)<br>Primary purpose: Treatment | NACHO Consortium, Memphis, TN, USA<br>Texas Children’s Hospital, Houston, TX, USA |
| A Combination of Vemurafenib, Cytarabine and 2-Chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation (NCT03585686) | Drug: Vemurafenib<br>Drug: Cytarabine<br>Drug: 2-Chlorodeoxyadenosine | Intervention model: Single-group assignment<br>Masking: None (open label)<br>Primary purpose: Treatment | Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation |
| Inherited Genetic Susceptibility in Langerhans Cell Histiocytosis (LCH) (NCT04100408) | Other: Biospecimen collection<br>Other: Laboratory biomarker analysis<br>Other: Questionnaire administration | Observational model: Family-based<br>Time perspective: Prospective | Baylor College of Medicine/ Dan L. Duncan Comprehensive Cancer Center at Baylor St. Luke’s Medical Center, Houston, TX, USA |
| Study title (ClinicalTrials.gov identifier) | Interventions | Study design | Locations |
|------------------------------------------|---------------|--------------|------------|
| A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis (NCT031277079) | Behavioral: Trail Making Test parts A and B Behavioral: Brief Test of Attention Behavioral: Symbol Span (and 8 more) | Observational model: Cohort Time perspective: Prospective | Memorial Sloan Kettering Basking Ridge, Basking Ridge, NJ, USA Memorial Sloan Kettering Monmouth, Middletown, NJ, USA Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, NY, USA (and 1 more) |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620) | Procedure: Biopsy Procedure: Biospecimen collection Drug: Ensartinib (and 12 more) | Allocation: Nonrandomized Intervention model: Parallel assignment Masking: None (open label) Primary purpose: Screening | Children's Hospital of Alabama, Birmingham, AL, USA Cardon Children’s Medical Center, Mesa, AZ, USA Phoenix Children’s Hospital, Phoenix, AZ, USA (and 143 more) |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250) | Other: Laboratory biomarker analysis Drug: Palbociclib Other: Pharmacological study | Intervention model: Single-group assignment Masking: None (open label) Primary purpose: Treatment | Children’s Hospital of Alabama, Birmingham, AL, USA Cardon Children’s Medical Center, Mesa, AZ, USA Phoenix Children’s Hospital, Phoenix, AZ, USA (and 93 more) |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03698994) | Other: Pharmacokinetic study Drug: Ulixertinib | Intervention model: Single-group assignment Masking: None (open label) Primary purpose: Treatment | Children’s Hospital of Alabama, Birmingham, AL, USA Cardon Children’s Medical Center, Mesa, AZ, USA Arkansas Children’s Hospital, Little Rock, AR, USA (and 94 more) |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) (NCT03233204) | Drug: Olaparib | Intervention model: Single-group assignment Masking: None (open label) Primary purpose: Treatment | Children’s Hospital of Alabama, Birmingham, AL, USA Cardon Children’s Medical Center Mesa, AZ, USA Arkansas Children’s Hospital, Little Rock, AR, USA (and 102 more) |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) (NCT03210714) | Drug: Erdafitinib Other: Laboratory biomarker analysis Other: Pharmacological study | Intervention model: Single-group assignment Masking: None (open label) Primary purpose: Treatment | Children’s Hospital of Alabama, Birmingham, AL, USA Cardon Children’s Medical Center, Mesa, AZ, USA Arkansas Children’s Hospital, Little Rock, AR, USA (and 103 more) |
### Table 2: Active clinical trials recruiting patients with Langerhans cell histiocytosis and related disorders (Continued)

| Study title (ClinicalTrials.gov identifier) | Interventions | Study design | Locations |
|--------------------------------------------|---------------|--------------|-----------|
| PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678) | Other: Laboratory biomarker analysis Other: Pharmacological study Drug: Samotolisib | Intervention model: Single-group assignment Masking: None (open label) Primary purpose: Treatment | Children’s Hospital of Alabama, Birmingham, AL, USA Cardon Children’s Medical Center, Mesa, AZ, USA Arkansas Children’s Hospital, Little Rock, AR, USA (and 104 more) |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | Drug: Tazemetostat | Intervention model: Single-group assignment Masking: None (open label) Primary purpose: Treatment | Children’s Hospital of Alabama, Birmingham, AL, USA Cardon Children’s Medical Center, Mesa, AZ, USA Phoenix Children’s Hospital, Phoenix, AZ, USA (and 106 more) |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704) | Drug: Larotrectinib Drug: Larotrectinib sulfate | Intervention model: Single-group assignment Masking: None (open label) Primary purpose: Treatment | Children’s Hospital of Alabama, Birmingham, AL, USA Cardon Children’s Medical Center, Mesa, AZ, USA Arkansas Children’s Hospital, Little Rock, AR, USA (and 105 more) |
| CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation (NCT01966367) | Biological: CD34 stem cell selection therapy | Intervention model: Single-group assignment Masking: None (open label) Primary purpose: Treatment | NewYork-Presbyterian Morgan Stanley Children’s Hospital, Columbia University, New York, NY, USA |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) (NCT03220035) | Other: Laboratory biomarker analysis Drug: Vemurafenib | Intervention model: Single-group assignment Masking: None (open label) Primary purpose: Treatment | Children’s Hospital of Alabama, Birmingham, AL, USA Cardon Children’s Medical Center, Mesa, AZ, USA Arkansas Children’s Hospital, Little Rock, AR, USA (and 103 more) |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (NCT01652092) | Drug: Alemtuzumab 0.3 mg Drug: Cyclophosphamide Drug: Busulfan (and 6 more) | Allocation: Nonrandomized intervention model: Single-group assignment Masking: None (open label) Primary purpose: Treatment | Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA |
acceptable, single-agent cytarabine or cladribine has been the preferred first-line option, mostly to minimize steroid-induced toxicity and neuropathy [17]. A review of the management of 58 adults with LCH demonstrated significantly higher response with cytarabine than with vinblastine/prednisone, which also presented worse toxicity with 75% grade 3–4 neuropathy [18]. Recurrences in adults are common. Besides the use of other cytotoxic agents such as clofarabine, the BRAF inhibitor vemurafenib has demonstrated excellent, albeit transient, responses in patients with BRAF V600E mutation [19]. The role of consolidation with allogeneic stem cell transplant is unclear. A review of 87 patients with high-risk LCH who underwent allogeneic transplant demonstrated greater than 70% long-term survival with higher relapse rates with reduced-intensity conditioning [12, 20]. A literature review of LCS described dramatic variation in management from chemotherapy to surgery, radiation, or a combination of them. Chemotherapy regimens were CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-based with mixed results. Survival was overall poor, 58% at 1 year, and outcomes were poorer in disseminated presentations [12].

Our case highlights the refractoriness of LCH in adults. Agents known to have activity in LCH demonstrated suboptimal responses. Attention to specific events during our patient’s presentation highlight important biologic characteristics of LCH. Molecular therapy was not possible, because no targetable mutation was identified. One central finding was the detection of LCS by EGD biopsy. Although our patient presented with symptomatic multisystem disease that required systemic therapy, the LCS component was minute. A more intensive first-line therapy was contemplated but was believed not to be indicated, considering that the presentation was mostly of LCH with a negligible LCS component with normal CBC, LDH, and BMBx. The best response was achieved after an AML induction/salvage regimen (cladribine, cytarabine, and filgrastim with idarubicin [CLAG-Ida]) that was intentionally chosen in view of the described activity of cladribine in LCH [5, 21]. One is left to wonder if our patient’s outcome would have been different had he received intensive induction chemotherapy for what was ultimately a presentation of myeloid sarcoma.

CNS involvement was another critical event. Although our patient had no suggestion of CNS involvement at initial staging, an ischemic cerebrovascular accident believed to be closely related to the DIC was the hallmark of presentation at disease progression/transformation to AML. Nonetheless, the most intriguing aspect of CNS involvement was the acute development of diplopia after the first dose of G-CSF administered as part of CLAG-Ida. The potential relationship between CNS involvement and G-CSF was highlighted during salvage, when the resolved diplopia recurred after a dose of pegfilgrastim. Numerous serum cytokines, including G-CSF, have been associated with the pathogenesis of LCH [22, 23]. The timing between growth factor injection and development of neurologic deficits implies a potential correlation.

---

**Table 2** Active clinical trials recruiting patients with Langerhans cell histiocytosis and related disorders (Continued)

| Study title (ClinicalTrials.gov identifier) | Interventions | Study design | Locations |
|--------------------------------------------|---------------|--------------|-----------|
| Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations (NCT02124772) | Drug: Trametinib  
Drug: Dabrafenib | Allocation: Nonrandomized  
Masking: None (open label)  
Primary purpose: Treatment | Novartis Investigative Site, Phoenix, AZ, USA  
Novartis Investigative Site, San Francisco, CA, USA  
Novartis Investigative Site, Baltimore, MD, USA (and 13 more) |
| Pediatric Long-Term Follow-up and Rollover Study (NCT03975829) | Drug: Dabrafenib  
Drug: Trametinib | Intervention model: Single-group assignment  
Masking: None (open label)  
Primary purpose: Treatment | Columbia University Medical Center, New York, NY, USA |
| CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant (NCT02061800) | Device: CliniMACS CD34+ reagent system (Miltenyi Biotech, Bergisch Gladbach, Germany)  
Drug: Thiotepa  
Drug: Cyclophosphamide (and 6 more) | Allocation: Nonrandomized  
Intervention model: Parallel assignment  
Masking: None (open label)  
Primary purpose: Treatment | Columbia University Medical Center, New York, NY, USA |

List is current as of October 25, 2019. Adapted from ClinicalTrials.gov
The homozygous loss of CDKN2A at 9p21 was also an interesting finding when analyzing the cytogenetic profile of our patient’s tumor. In contrast to its counterpart of LCH, a recent study demonstrated frequent homozygous loss of CDKN2A/B locus (9p21) and both MAP2K1 and NRAS genes mutations in LCS, which may provide a future basis for potential targeted therapy [24].

In summary, LCH remains an exceedingly rare entity in adults, frequently presenting as multisystem disease with risk organ involvement. Although therapeutic targets such as BRAF V600E mutations have been identified, therapeutic options remain limited. An intensive AML induction regimen should be strongly considered for LCH presentations with suggestion of an LCS component with cautious use of growth factors and particular attention to CNS involvement. In view of the limited number of effective therapeutic interventions, patients with refractory cases or atypical presentations of LCH and LCH-related disorders should be encouraged to enroll in one of multiple active clinical trials (Table 2).

Acknowledgements
Not applicable.

Authors’ contributions
LEA and IS were involved in data collection, designed the case report protocol, reviewed the existing literature, and drafted the paper. AA and MFL were involved in the care of the patient, designed the treatment protocol, and supervised the data collection. JC analyzed the pathology slides and submitted the figures and footnotes. AA codrafted, reviewed, and approved the final manuscript. All authors read and approved the final manuscript.

Authors’ information
LEA and IS are resident physicians at the Department of Internal Medicine at the University of Miami and Jackson Memorial Hospital. MFL works as assistant professor of gastroenterology and is the medical director of the Gastrointestinal Endoscopy Unit at Jackson Memorial Hospital and at the University of Miami Miller School of Medicine. JC works as associate professor of pathology at the University of Miami. She is the director of the Immunohistochemistry Laboratory and associate program director at the Department of Pathology and Laboratory Medicine at the University of Miami and Jackson Memorial Hospital. AA works as assistant professor of medicine at the University of Miami and is a member of the lymphoma program at the University of Miami Sylvester Comprehensive Cancer Center.

Funding
The authors have no sources of funding to declare.

Availability of data and materials
This report does not contain any data. This section is not applicable.

Ethics approval and consent to participate
No ethics approval was required for the drafting of this report.

Consent for publication
Written informed consent was obtained from the patient’s next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Hematology and Medical Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 2 Department of Gastroenterology, Loyola University Medical Center, Maywood, IL, USA. 3 Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA. 4 Department of Gastroenterology, University of Miami Miller School of Medicine, Miami, FL, USA. 5 Department of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Clinical Research Building, 1120 NW 14th Street, Suite 650B, Miami, FL 33136, USA.

Received: 21 June 2019 Accepted: 23 July 2020
Published online: 27 September 2020

References
1. Stockschlaeder M, Sucker C. Adult Langerhans cell histiocytosis. Eur J Haematol. 2006;76:363–8.
2. Broadbent V, Egele RS, Nesbit ME Jr. Langerhans cell histiocytosis: clinical and epidemiological aspects. Br J Cancer Suppl. 1994;23:S11–6.
3. Baumgartner I, von Hochstetter A, Baumert B, et al. Langerhans’ cell histiocytosis in adults. Med Pediatr Oncol. 1997;28(1):19–49.
4. Lahay ME. Histiocytosis-X: an analysis of prognostic factors. J Pediatr. 1975; 87:184–9.
5. Saven A, Figueroa ML, Piro LD, et al. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med. 1993;329(10):734–5.
6. Badalian-Very G, Vergilio JA, Deraj B, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–23.
7. Sahn F, Capper D, Preusser M, et al. BRAF(V600E) mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120(12):e28–34.
8. Arico M, Girschikofsky M, Genereau T, et al. Langerhans cell histiocytosis in adults: report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003;39:2341–8.
9. French Langerhans’ Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child. 1996;75(1):17–24.
10. Singh AD, Montgomery EA. Gastrointestinal tract Langerhans cell histiocytosis: a clinicopathologic study of 12 patients. Am J Surg Pathol. 2011;35(2):305–10.
11. Zwerdling T, Wren S, Shane L, et al. Langerhans cell sarcoma: case report and review of world literature. J Pediatr Hematol Oncol. 2014;36(6):419–25.
12. Howard JE, Dwivedi RC, Masterson L, et al. Langerhans cell sarcoma: a systematic review. Cancer Treat Rev. 2015;41(4):320–31.
13. Nakamine H, Yamakawa M, Yoshino T, et al. Langerhans cell histiocytosis and Langerhans cell sarcoma: current understanding and differential diagnosis. J Clin Exp Hematol. 2015;65(2):109–19.
14. Ferringer T, Banks PM, Metcalf JS. Langerhans cell sarcoma. Am J Dermatopathol. 2006;28:362–9.
15. Pileri S, Grogan TM, Harris NL, et al. Tumors of histiocytosis and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41:1–29.
16. Duan MH, Han X, Li J, et al. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: a single-center retrospective study. Leuk Res. 2016;42:43–6.
17. Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-HistoNet. Orphanet J Rare Dis. 2013;2:72.
18. Cantu MA, Lupo PJ, Bilgi M, et al. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012;7(8):e43257.
19. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(19):1495–500.
20. Lea L, Nanduri V, Baker KS, et al. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol. 2015;169(3):711–8.
21. Saven A, Foon KA, Piro LD, et al. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med. 1994; 121(6):430–2.
22. Morimoto A, Oh Y, Nakamura S, et al. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis. Cytokine. 2017;97:73–9.
23. Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer Suppl. 1994;23:S37–40.
24. Xerri L, Adélaïde J, Popovici C, et al. CDKN2A/B deletion and double-hit mutations of the MAPK pathway underlie the aggressive behavior of Langerhans cell tumors. Am J Surg Pathol. 2018;42(2):150–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.